"This means that many drug companies are becoming more and more dependent on a narrower base of products. Celgene $CELG, is a good example. It reported $11.2 billion in revenue last year, and almost $7 billion of that came from Revlimid, a cancer drug."
"Overall, the wound care industry is showing renewed signs of growth as the demand for the products remain strong due to the aging population. There will also be a shift in focus in the coming years towards advanced wound care products including biological dressings and negative pressure wound therapy devices."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.